These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 27750326)

  • 21. [The critical role of research evidence in the framework of health technology assessment].
    Sauerland S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Mar; 49(3):251-6. PubMed ID: 16477456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reviewing the evidence to inform the population of cost-effectiveness models within health technology assessments.
    Kaltenthaler E; Tappenden P; Paisley S
    Value Health; 2013; 16(5):830-6. PubMed ID: 23947977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conceptual modeling for Prospective Health Technology Assessment.
    Gantner-Bär M; Djanatliev A; Prokosch HU; Sedlmayr M
    Stud Health Technol Inform; 2012; 180():33-7. PubMed ID: 22874147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bayesian methods in health technology assessment: a review.
    Spiegelhalter DJ; Myles JP; Jones DR; Abrams KR
    Health Technol Assess; 2000; 4(38):1-130. PubMed ID: 11134920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1.
    Caro JJ; Briggs AH; Siebert U; Kuntz KM;
    Value Health; 2012; 15(6):796-803. PubMed ID: 22999128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncotyrol--Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research.
    Siebert U; Jahn B; Rochau U; Schnell-Inderst P; Kisser A; Hunger T; Sroczynski G; Mühlberger N; Willenbacher W; Schnaiter S; Endel G; Huber L; Gastl G;
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):330-40. PubMed ID: 26354133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
    Siebert U; Rochau U; Claxton K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A model for technology assessment applied to pulse oximetry. The Technology Assessment Task Force of the Society of Critical Care Medicine.
    Crit Care Med; 1993 Apr; 21(4):615-24. PubMed ID: 8472583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Epidemiological studies in the HTA evaluation process].
    Behrens T; Ahrens W
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Mar; 49(3):264-71. PubMed ID: 16477457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advantages and disadvantages of discrete-event simulation for health economic analyses.
    Caro JJ; Möller J
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):327-9. PubMed ID: 26967022
    [No Abstract]   [Full Text] [Related]  

  • 31. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7.
    Eddy DM; Hollingworth W; Caro JJ; Tsevat J; McDonald KM; Wong JB;
    Value Health; 2012; 15(6):843-50. PubMed ID: 22999134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment.
    Beca J; Husereau D; Chan KKW; Hawkins N; Hoch JS
    Pharmacoeconomics; 2018 Jan; 36(1):7-15. PubMed ID: 29110141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health technology assessment and primary data collection for reducing uncertainty in decision making.
    Goeree R; Levin L; Chandra K; Bowen JM; Blackhouse G; Tarride JE; Burke N; Bischof M; Xie F; O'Reilly D
    J Am Coll Radiol; 2009 May; 6(5):332-42. PubMed ID: 19394574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Similarities and differences between stakeholders' opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey.
    Vokó Z; Cheung KL; Józwiak-Hagymásy J; Wolfenstetter S; Jones T; Muñoz C; Evers SM; Hiligsmann M; de Vries H; Pokhrel S;
    Health Res Policy Syst; 2016 May; 14(1):38. PubMed ID: 27230485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluations conducted by Canadian health technology assessment agencies: where do we stand?
    Tarride JE; McCarron CE; Lim M; Bowen JM; Blackhouse G; Hopkins R; O'Reilly D; Xie F; Goeree R
    Int J Technol Assess Health Care; 2008; 24(4):437-44. PubMed ID: 18828938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toward a sustainable European Network for Health Technology Assessment. The EUnetHTA project.
    Kristensen FB; Chamova J; Hansen NW
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Mar; 49(3):283-5. PubMed ID: 16453137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and review of cost-effectiveness model parameters: a qualitative study.
    Kaltenthaler E; Essat M; Tappenden P; Paisley S
    Int J Technol Assess Health Care; 2014 Jul; 30(3):333-40. PubMed ID: 25089856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Technology assessment in critical care: understanding statistical analyses used to assess agreement between methods of clinical measurement.
    Szaflarski NL; Slaughter RE
    Am J Crit Care; 1996 May; 5(3):207-16. PubMed ID: 8722924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies.
    Drummond M; Manca A; Sculpher M
    Int J Technol Assess Health Care; 2005; 21(2):165-71. PubMed ID: 15921055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health technology assessment.
    Hailey D
    Singapore Med J; 2006 Mar; 47(3):187-92; quiz 193. PubMed ID: 16518551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.